Table II.

Outcome of patients with cytogenetic abnormalities

Patient	Dx to MDACC, months	Cytogenetics at presentation to MDACC	Subsequent Cytogenetics	Dx to Clonal Evolution, months	Transformed To	Dx to Transformation, months	Dx to LFU, months (years)	Current Status
1	0	(47,XY,C+)-30%;(46,XY)-70%			MFIB	118	144 (12)	Dead
2	0	46,XX,del(7)(q22),del(7)(q22q32),-22,+mar[13]; 43- 46,XX,-5,del(7)(q22),del(7)(q22q32),-22,+1- 3mar[cp7]					8 (1)	Dead
3	1	46,XY,T(12;21)(Q21;Q21)[5]; 46,XY[15]			MFIB	51	93 (8)	Dead
4	2	47XX,+9[13]; 46XX[7]					47 (4)	Alive
5	3	46XY,+1,DER(1;22)(Q10;Q10)[17]; 46,XY[3]	46,XY[20]				61 (5)	Alive
6	4	46,XY,del(12)(q15q22)[6]; 46,XY[13]	46,XY,del(12)(q15q22)[15]; 46,XY,del(12)(q15q22),del(20)(q13)[2]; 46,XY[3]	34	MFIB	106	121 (10)	Alive
7	40	47,XX,+9[9]; 46XX[11]					69 (6)	Alive
8	52	46,XY,DER(21)T(1;21)(Q12;p13)[7]; 46,XY[13]					81 (7)	Alive
9	114	46,XX,DEL(11)(Q13)[20]			MFIB	115	117 (10)	Dead
10	132	46,XX,DEL(20)(Q11.2Q13.1)[15]; 46,XX[3]					139 (12)	Dead
11	150	46,XY,del(6)(q21q25),add(11)(p11.2)[2]; 46,XY[28]					221 (18)	Alive
12	176	47,XX,+9[17]					204 (17)	Alive
13	287	46XY DEL(20)(Q11.2)[5]; 46,XY[15]					356 (30)	Dead
14	0	46,XY[20]	42,XY,del(2)(p22),-5,del(6)(q21q25),add(7)(p11.1),del(7)(q22),add(11)(p11.1),-13, -16,del(16)(q22q24),add(17)(p11.1),del(18)(q22),del(20)(q11.2q13.1),-22[16]; 38- 39,XY,-4,-5,-7,-10,del(16)(q22q24),-17,-18[cp2]; 46,XY[2]	34	AML	33	37 (3)	Dead
15	0	46,XX(20Q-)[1]; 46,XX[21]	46,XX(20q-)[10]; 46,XX[9]	94			292 (24)	Dead
16	1	46,XX[20]	46,XX,dup(1)(q21q32)[20]	308	MFIB	303	324 (27)	Dead
17	57	46,XY[20]	38-45,XY,add(5){q11.2},-7,-15[7],-22[8]+0-2mar[cp18]; 46,XY[2]	107	MDS	104	107 (9)	Dead
18	101	46,XY[20]	46,XY,der(6)t(1;6)(q25;p25)[18]; 46,XY,der(6)t(1;6)(q25;p25) exhibiting random changes[1]; 46,XY,del(7)(q22)[1]	134	AML	114	133 (11)	Alive
19	221	46,XX[20]	46,XX,der(7)t(1;7)(q21;q36)[15]; 46,XX[5]	324			322 (27)	Dead

Dx = diagnosis; LFU = last follow up; AML = acute myeloid leukemia; MDS = myelodysplastic syndrome; MFIB = myelofibrosis